A5053134500- HIV Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Reproductive System and Pregnancy
- HIV/AIDS drug development and treatment
- Autoimmune Bullous Skin Diseases
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Tuberculosis Research and Epidemiology
- Complement system in diseases
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Hormonal Regulation and Hypertension
- CRISPR and Genetic Engineering
- Electrolyte and hormonal disorders
- Hepatitis C virus research
- Influenza Virus Research Studies
- Blood groups and transfusion
- Toxin Mechanisms and Immunotoxins
- Platelet Disorders and Treatments
- Respiratory Support and Mechanisms
- Nitric Oxide and Endothelin Effects
- Glycosylation and Glycoproteins Research
- Sepsis Diagnosis and Treatment
Argenx (Belgium)
2022-2024
Ghent University Hospital
2014-2022
Ablynx (Belgium)
2022
Ghent University
2012-2018
Ragon Institute of MGH, MIT and Harvard
2011-2018
The Royal Free Hospital
2017
University College London
2017
Massachusetts Institute of Technology
2011-2016
Although the development of a fully protective HIV vaccine is ultimate goal research, to date only one trial, RV144, has successfully induced weakly response. The 31% protection from infection achieved in RV144 trial was linked induction nonneutralizing antibodies, able mediate antibody-dependent cell-mediated cytotoxicity (ADCC), suggestive an important role Fc-mediated functions protection. Similarly, antiviral activity recently shown play critical actively suppressing viral reservoir, but...
Journal Article Single-cell analysis of the dynamics and functional outcomes interactions between human natural killer cells target Get access Yvonne J. Yamanaka, Yamanaka Department Biological Engineering, Massachusetts Institute Technology, 77 Ave., Cambridge, MA 02139, USA Search for other works by this author on: Oxford Academic Google Scholar Christoph T. Berger, Berger The Ragon MGH, MIT, Harvard, Charlestown Navy Yard, Boston, 02129, Magdalena Sips, Sips Patrick C. Cheney, Cheney...
Immunoglobulin G (IgG) levels are maintained by the IgG-recycling neonatal Fc-receptor (FcRn). Pemphigus vulgaris and pemphigus foliaceus debilitating autoimmune disorders triggered IgG autoantibodies against mucosal epidermal desmogleins. Recently, a phase 2 clinical trial (NCT03334058; https://clinicaltrials.gov/NCT03334058) was completed in participants with using efgartigimod, an FcRn inhibitor, combination prednisone. Efgartigimod demonstrated early effect on diease activity well...
Bullous pemphigoid (BP) is an autoimmune blistering disease whereby patients develop autoantibodies against the basement membrane zone (BMZ) antigens BP180 and/or BP230. These exert numerous pathogenic Fc receptor (FcR)-dependent and FcR-independent effects (Cole et al., 2022Cole C. Vinay K. Borradori L. Amber K.T. Insights Into Pathogenesis of Pemphigoid: The Role Complement-Independent Mechanisms.Front Immunol. 2022; 13912876Crossref Scopus (15) Google Scholar), can be readily visualized...
Abstract Binding to the neonatal Fc receptor (FcRn) extends serum half-life of IgG, and antagonizing this interaction is a promising therapeutic approach in IgG-mediated autoimmune diseases. Fc-MST-HN, designed for enhanced FcRn binding capacity, has not been evaluated context full-length antibody, structural properties attached Fab regions might affect FcRn-mediated intracellular trafficking pathway. Here we present comprehensive comparative analysis IgG salvage pathway between two...
Antagonism of the neonatal Fc receptor (FcRn) by efgartigimod has been studied in several autoimmune diseases mediated immunoglobulin G (IgG) as a therapeutic approach to remove pathogenic IgGs. Whereas reduction titres demonstrated efficacy multiple diseases, reducing total IgG could potentially increase infection risk patients receiving FcRn antagonists. The objective this study was analyse effect antagonism with on existing protective antibody and ability mount an immune response after...
BackgroundA wide range of host restriction factors (RF) become upregulated upon HIV-1 infection to suppress viral infectivity and may aid viremic control in vivo. This cross-sectional study evaluated RFs dependency HIV infected individuals with progressive or non-progressive infection, as well early late treated cohorts that exhibit different viro-immunological profiles due differences timing treatment-initiation.MethodsThe expression profile IFIT1, MX1, APOBEC3G, SAMHD1, BST2 (encoding...
Septic shock is the leading cause of death in intensive care units worldwide, resulting from a progressive systemic inflammatory reaction causing cardiovascular and organ failure. Nitric oxide (NO) potent vasodilator inhibition NO synthases (NOS) can increase blood pressure septic shock. However, NOS does not improve outcome, on contrary, certain donors may even provide protection. In addition, produce superoxide case substrate or cofactor deficiency oxidation. We hypothesized that excessive...
The neonatal Fc receptor (FcRn) is important for numerous cellular processes that involve antibody recycling and trafficking. A major function of FcRn IgG half-life prolongation, blockade results in a reduction autoantibodies IgG-mediated autoimmune diseases. In epithelial cells, functions different from recycling, such as transcytosis intestinal cells. pemphigus vulgaris, an disease the epidermis, directed against desmosomal adhesion proteins, especially desmoglein-3 -1, cause loss...
The neonatal Fc receptor, FcRn, recycles immunoglobulin G (IgG), extending its half-life and serum concentration 1• Efgartigimod is a human IgG1 fragment, natural ligand of engineered for increased affinity FcRn 2• was designed to outcompete endogenous IgG, preventing recycling promoting lysosomal degradation without impacting production 2-5 o Targeted reduction all IgG subtypes No impact on IgM or IgA in albumin levels increase cholesterol 1.
Abstract Introduction: To date, with no prophylactic human immunodeficiency virus (HIV) vaccine available, HIV incidence rates remain undefeated. Despite full virological suppression, HIV+ individuals exhibit a higher rate of cardiovascular disorders and cancers what is attributed to the residual, persistent levels immune activation. Methods: We have established Virological Immunological Monitoring (VIM) platform forty VIM samples that included treated immunological responders (IRs) or...
Background Data from the RV144 HIV vaccine trial showed a moderate protection infection in absence of neutralizing antibodies or CTL activity. In contrast, all vaccinees mounted robust HIV-specific binding antibodies, that may have provided some level through their capacity to recruit antibody dependent cellular cytotoxicity (ADCC). The an ADCC relies on its ability interact with Fc-receptor, FCgRIII (CD16), expressed Natural Killer (NK) cells. However, little is known about innate immune...